Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature
Authors:
- Jeffrey T. MalikJMJeffrey T. Malik
- Julie E. ChangJCJulie E. Chang
- 1 June 2011
- journal article
- case report
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 11 (3) , 289-292
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials NetworkBlood, 2009
- A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008Annals of the Rheumatic Diseases, 2008
- Hodgkin’s lymphoma following treatment with etanercept in ankylosing spondylitisRheumatology International, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel DiseaseGastroenterology, 2006
- Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: Case report and review of the literatureScandinavian Journal of Gastroenterology, 2006
- Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsAnnals of the Rheumatic Diseases, 2005
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- The relationship between infliximab treatment and lymphoma in Crohn's diseaseGastroenterology, 1999